Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase II Study Of Saracatinib (AZD0530), A Src Inhibitor, Administered Orally Daily To Patients With Advanced Thymic Malignancies Wakelee, H. A., Gubens, M. A., Burns, M., Barbeau, S. L., Perkins, S., Pedo-Salcedo, M. G., Loehrer, P. J. LIPPINCOTT WILLIAMS & WILKINS. 2010: S528–S528
View details for Web of Science ID 000284994100072